89829-62-9

Basic information

• Product Name: 2-Thiazolecarboximidamide, N-hydroxy-
• Synonyms: 2-Thiazolecarboximidamide, N-hydroxy-;N-hydroxy-2-ThiazolecarboxiMidaMide
• CAS NO: 89829-62-9
• Molecular Formula: C4H5N3OS
• Molecular Weight: 143.17
• Mol File: 89829-62-9.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-Thiazolecarboximidamide, N-hydroxy-(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Thiazolecarboximidamide, N-hydroxy-(89829-62-9)
• EPA Substance Registry System: 2-Thiazolecarboximidamide, N-hydroxy-(89829-62-9)

Safety Data

• Hazardous Substances Data: 89829-62-9(Hazardous Substances Data)

Upstream product

• 1452-16-0 thiazole-2-carbonitrile 

Relevant articles and documents

COMPOUNDS HAVING AN ETHR INHIBITING ACTIVITY - USE OF SAID COMPOUNDS AS DRUGS - PHARMACEUTICAL COMPOSITION AND PRODUCT CONTAINING SAID COMPOUNDS

The present invention relates to compounds of Formula (I), wherein R1 is chosen among the following radicals : (II); (III); (IV), (V), (VI) (VII) and n= 1 or 2 and m=1 or 2 with the proviso that m=2 when R1 is (VIII). The present invention also relates to the use thereof as drugs, more particularly in the treatment of mycobacterial infections and more particularly in the treatment of tuberculosis.

Dihydroxypyrimidine-4-carboxamides as novel potent and selective HIV integrase inhibitors

Human immunodeficiency virus type-1 (HIV-1) integrase, one of the three constitutive viral enzymes required for replication, is a rational target for chemotherapeutic intervention in the treatment of AIDS that has also recently been confirmed in the clinical setting. We report here on the design and synthesis of N-benzyl-5,6-dihydroxypyrimidine-4-carboxamides as a class of agents which exhibits potent inhibition of the HIV-integrase-catalyzed strand transfer process. In the current study, structural modifications on these molecules were made in order to examine effects on HIV-integrase inhibitory potencies. One of the most interesting compounds for this series is 2-[1-(dimethylamino)-1-methylethyl]-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine- 4-carboxamide 38, with a CIC95 of 78 nM in the cell-based assay in the presence of serum proteins. The compound has favorable pharmacokinetic properties in preclinical species (rats, dogs, and monkeys) and shows no liabilities in several counterscreening assays, highlighting its potential as a clinically useful antiviral agent.